FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285930> ?p ?o ?g. }

• W4379285930 endingPage "1018" @default.
• W4379285930 startingPage "1018" @default.
• W4379285930 abstract "1018 Background: Endocrine therapy (ET) combined with a CDK4/6 inhibitor is standard of care for hormone receptors-positive (HR+) advanced breast cancer (ABC). In France, 33% of BC are diagnosed in women aged 70 and older, contrasting with their constant underrepresentation in clinical trials. PALOMAGE, a prospective, observational, longitudinal real-life program, assessed the feasibility of ET combined with palbociclib (PAL), specifically in women aged ≥70 years with HR+ HER2- ABC. Methods: Depending on prior treatment for ABC and time of relapse, women were enrolled in two cohorts: ET-sensitive disease (no prior systemic treatment for ABC and no relapse within 1 year after adjuvant ET, cohort A) or ET-resistant disease (relapse on adjuvant ET or < 1 year after completion, or prior treatment for ABC, cohort B). Data collected at baseline and then every 3 months included: sociodemographic, clinical, biological, disease- and treatment-related, response, quality of life (QoL; EORTC QLQ-C30 and ELD14), geriatric (G8 and Geriatric-COre DatasEt [G-CODE]) and safety. Results of feasibility in cohort B (rate of PAL discontinuation at 6 months 28.8%) were reported at SABCS 2021. Here, we report results in cohort A, based on the rate of PAL discontinuation at 18 months for any reason as the primary endpoint. Secondary endpoints included time-to-treatment failure (TTF), progression-free survival (PFS), QoL, and safety. Results: For this analysis, 362 patients (from 130 sites) with sufficient data were considered: median age was 78 years (range: 70-94), ECOG was ≥2 in 19.2%, and visceral metastases was present in 39.8%. PAL starting dose was 125 mg, 100 mg, and 75 mg in 80.0%, 14.4%, and 5.6% of patients, respectively, and combined with an aromatase inhibitor in 93.6% or fulvestrant in 6.4%. Baseline scores showed G8 ≤14, ADL ≤5 and IADL ≤3 in 68.2%, 15.5% and 29.4% of patients, respectively. Among the 362 patients, 327 were evaluable for the primary endpoint. With a median follow-up of 20.7 months (95% CI: 18.8-22.0), the 18-month discontinuation rate for PAL was 41.9% (95% CI: 36.6%-47.2%), due to disease progression (20.8%), toxicity (7.7%), patient’s choice (6.7%), death (4.6%), or other reason (2.1%). Median TTF and PFS were 22.7 months (95% CI: 19.1–26.0) and 28.1 months (95% CI: 25.6-not reached), respectively. Safety profile showed (360 patients evaluable) 54.4% all grade neutropenia (1.1% febrile neutropenia). Impact of geriatric status on effectiveness and safety will be presented, together with the evolution of QoL. Conclusions: In a large real-life population of older women with G8 impaired in two thirds and with ET-sensitive ABC, discontinuation rate of PAL at 18 months was 41.9%, with a median PFS of 28.1 months, consistent with PALOMA2 results. Optimized ET combined with PAL is feasible in unselected older women with HR+ ET-sensitive ABC." @default.
• W4379285930 created "2023-06-05" @default.
• W4379285930 creator A5003745000 @default.
• W4379285930 creator A5005973748 @default.
• W4379285930 creator A5006022529 @default.
• W4379285930 creator A5018262486 @default.
• W4379285930 creator A5019732783 @default.
• W4379285930 creator A5035439475 @default.
• W4379285930 creator A5039528334 @default.
• W4379285930 creator A5041511829 @default.
• W4379285930 creator A5050181071 @default.
• W4379285930 creator A5066779941 @default.
• W4379285930 creator A5068615601 @default.
• W4379285930 creator A5068647863 @default.
• W4379285930 creator A5071961833 @default.
• W4379285930 creator A5077714048 @default.
• W4379285930 creator A5078155731 @default.
• W4379285930 creator A5080222443 @default.
• W4379285930 creator A5092084690 @default.
• W4379285930 date "2023-06-01" @default.
• W4379285930 modified "2023-09-30" @default.
• W4379285930 title "First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program." @default.
• W4379285930 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1018" @default.
• W4379285930 hasPublicationYear "2023" @default.
• W4379285930 type Work @default.
• W4379285930 citedByCount "0" @default.
• W4379285930 crossrefType "journal-article" @default.
• W4379285930 hasAuthorship W4379285930A5003745000 @default.
• W4379285930 hasAuthorship W4379285930A5005973748 @default.
• W4379285930 hasAuthorship W4379285930A5006022529 @default.
• W4379285930 hasAuthorship W4379285930A5018262486 @default.
• W4379285930 hasAuthorship W4379285930A5019732783 @default.
• W4379285930 hasAuthorship W4379285930A5035439475 @default.
• W4379285930 hasAuthorship W4379285930A5039528334 @default.
• W4379285930 hasAuthorship W4379285930A5041511829 @default.
• W4379285930 hasAuthorship W4379285930A5050181071 @default.
• W4379285930 hasAuthorship W4379285930A5066779941 @default.
• W4379285930 hasAuthorship W4379285930A5068615601 @default.
• W4379285930 hasAuthorship W4379285930A5068647863 @default.
• W4379285930 hasAuthorship W4379285930A5071961833 @default.
• W4379285930 hasAuthorship W4379285930A5077714048 @default.
• W4379285930 hasAuthorship W4379285930A5078155731 @default.
• W4379285930 hasAuthorship W4379285930A5080222443 @default.
• W4379285930 hasAuthorship W4379285930A5092084690 @default.
• W4379285930 hasConcept C121608353 @default.
• W4379285930 hasConcept C126322002 @default.
• W4379285930 hasConcept C143998085 @default.
• W4379285930 hasConcept C159110408 @default.
• W4379285930 hasConcept C188816634 @default.
• W4379285930 hasConcept C203092338 @default.
• W4379285930 hasConcept C2775930923 @default.
• W4379285930 hasConcept C2778715236 @default.
• W4379285930 hasConcept C2779744173 @default.
• W4379285930 hasConcept C2779951463 @default.
• W4379285930 hasConcept C530470458 @default.
• W4379285930 hasConcept C535046627 @default.
• W4379285930 hasConcept C71924100 @default.
• W4379285930 hasConcept C72563966 @default.
• W4379285930 hasConceptScore W4379285930C121608353 @default.
• W4379285930 hasConceptScore W4379285930C126322002 @default.
• W4379285930 hasConceptScore W4379285930C143998085 @default.
• W4379285930 hasConceptScore W4379285930C159110408 @default.
• W4379285930 hasConceptScore W4379285930C188816634 @default.
• W4379285930 hasConceptScore W4379285930C203092338 @default.
• W4379285930 hasConceptScore W4379285930C2775930923 @default.
• W4379285930 hasConceptScore W4379285930C2778715236 @default.
• W4379285930 hasConceptScore W4379285930C2779744173 @default.
• W4379285930 hasConceptScore W4379285930C2779951463 @default.
• W4379285930 hasConceptScore W4379285930C530470458 @default.
• W4379285930 hasConceptScore W4379285930C535046627 @default.
• W4379285930 hasConceptScore W4379285930C71924100 @default.
• W4379285930 hasConceptScore W4379285930C72563966 @default.
• W4379285930 hasFunder F4320307765 @default.
• W4379285930 hasIssue "16_suppl" @default.
• W4379285930 hasLocation W43792859301 @default.
• W4379285930 hasOpenAccess W4379285930 @default.
• W4379285930 hasPrimaryLocation W43792859301 @default.
• W4379285930 hasRelatedWork W2294069589 @default.
• W4379285930 hasRelatedWork W2593892593 @default.
• W4379285930 hasRelatedWork W2769683585 @default.
• W4379285930 hasRelatedWork W2912763149 @default.
• W4379285930 hasRelatedWork W3092326212 @default.
• W4379285930 hasRelatedWork W3203106735 @default.
• W4379285930 hasRelatedWork W4210295521 @default.
• W4379285930 hasRelatedWork W4220872882 @default.
• W4379285930 hasRelatedWork W4283528480 @default.
• W4379285930 hasRelatedWork W4379054559 @default.
• W4379285930 hasVolume "41" @default.
• W4379285930 isParatext "false" @default.
• W4379285930 isRetracted "false" @default.
• W4379285930 workType "article" @default.